Español
The growing complexity of bioprocesses in the pharmaceutical industry, particularly in the development of innovative therapies such as oligonucleotides, is accelerating the adoption of digital technologies capable of improving understanding,
Author Archives: syoligo
Solid-phase oligonucleotide synthesis (SPOS) is a highly efficient and reproducible process, but it has significant environmental limitations, primarily due to the high consumption of organic solvents and the generation of
Blog
World Book Day: three essential reads for gaining a deeper understanding of RNA and therapeutic oligonucleotides
Every 23 April, World Book Day invites us to reflect on the value of knowledge as a driving force for progress. In the field of biomedicine, the generation and transfer
Blog
Sylentis, a PharmaMar Group company, obtains Good Manufacturing Practice certification from the European Medicines Agency for its new industrial plant
This recognition from the European Medicines Agency (EMA) is one of the most demanding regulatory certifications. With this milestone, the company reinforces its commitment to operational excellence. Sylentis, empresa biofarmacéutica
Blog
Sylentis, compañía del Grupo PharmaMar, obtiene la certificación de Normas de Correcta Fabricación de la Agencia Europea de Medicamentos para su nueva planta industrial
Este reconocimiento de la Agencia Europea de Medicamentos (EMA) es una de las certificaciones reglamentarias más exigentes. Con este hito, la empresa refuerza su compromiso con la excelencia operativa. Sylentis,
The year 2025 has marked a very special milestone for Sylentis and the SYOLIGO project: the end of the third year of activity since its launch. Twelve months in which
The recent article “Recent Update on siRNA Therapeutics” from the International Journal of Molecular Sciences provides a comprehensive analysis of the state of siRNA-based therapies. Its conclusions are key to
Blog
IPCEI Health MED4CURE: the project Syoligo by Sylentis, example of biomedical innovation with an impact on health and employment
On 15 December 2025, the CDTI hosted the IPCEI Health MED4CURE conference in Madrid, a key event for the Spanish biomedical ecosystem that brought together institutional leaders, companies participating in
Cardiovascular diseases (CVD) remain the leading cause of death worldwide. Despite advances in conventional medicine, many of these conditions are still treated with “one-size-fits-all” therapies that fail to reflect the
